Nature CommunicationsGenetic & Genomic MedicinePeer-reviewed journal article
Preventing premature deaths through polygenic risk scores
Melisa Chuong, Deborah J. ThompsoniD, Michael E. WealeiD, Fernando Riveros-MckayiD, Nilesh J. SamaniiD, Daniel WellsiD, Vincent PlagnoliD, Gil McVeaniD, Euan Angus AshleyiD, Peter DonnellyiD, Seamus C. HarrisoniD, Jack William O’SullivaniD
Abstract
BackgroundPolygenic risk scores (PRS) have demonstrated predictive validity across a range of cohorts and diseases, but quantifying their clinical utility remains a challenge. As PRS can be derived from a single biological sample and remain stable throughout life, we explore the potential of PRS to optimize existing screening programs. MethodsVia an integrated modelling approach, we quantified the potential clinical benefits arising from a knowledge of PRS across seven diseases with existing screening programs (abdominal aortic aneurysm, breast cancer, colorectal cancer, coronary artery disease, hypertension, prostate cancer, and type 2 diabetes). We identified individuals at high genetic risk (PRS OR>2) and very high genetic risk (PRS OR>3) and estimated the optimal screening ages for these genetically high risk individuals, based on the equivalent risk to population-level risk at recommended screening ages. We then leveraged published data on differential mortality and other outcomes, with and without screening-based interventions, to assess the potential benefits of tailoring screening age based on genetic risk. We also estimated the case enrichment ratio, which is a ratio of the percentage of cases in the high PRS risk group and in the total population. FindingsVery high risk individuals reach the risk level associated with usual starting screening age on average 10.8 years earlier, high risk individuals 8.9 years earlier and reduced risk individuals (OR<0.5) 16.8 years later. During this time, case enrichment in the high risk group is between 1.7 and 3.0 depending on disease. Across all seven diseases, appropriate interventions following PRS-guided screening could reduce premature deaths in high risk individuals by 23.3%. ConclusionKnowledge of genetic risk, measured using PRS, has the potential to deliver substantial public health benefits when aggregated across conditions, and could reduce premature mortality by tailoring existing screening programs.
- organism: human
- assay: GWAS summary statistics
- research focus: benchmarking
- approach: statistical model
- Citations
- 4
- FWCI
- 11.87
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Polygenic and clinical risk scores and their impact on age at onset of cardiometabolic diseases and common cancers
Nina Mars, Jukka T. Koskela, … Samuli Ripatti·bioRxiv·Oct 30, 2019
- Performance of polygenic risk scores in screening, prediction, and risk stratification
Aroon Dinesh Hingorani, Jasmine Gratton, … NJ Wald·medRxiv·Feb 18, 2022
- A systematic framework for assessing the clinical impact of polygenic risk scores
Scott Kulm, Andrew R. Marderstein, … Olivier Elemento·medRxiv·Apr 6, 2020
- Prospective analysis of incident disease among individuals of diverse ancestries using genetic and conventional risk factors
Wei Wang, Nicholas Eriksson, … Suyash Shringarpure·medRxiv·Oct 23, 2023
- Effects of polygenic risk score communication on health outcomes: systematic review and meta-analysis
Luigi Russo, Nicolò Lentini, … John P. A. Ioannidis·medRxiv·Nov 4, 2025
- Contextualizing the Utility of Polygenic Risk Scores using Absolute Risk Models in Diverse Ancestry Populations
Martina Fu, Linda Kachuri, … Nilanjan Chatterjee·medRxiv·Jun 4, 2026